We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Hand-Held Analyzer Provides Critical Sepsis Information in 11 Minutes at POC

By LabMedica International staff writers
Posted on 20 Jun 2022
Print article
Image: Nanōmix eLab system utilizes patented multi-plex test cartridge technology (Photo courtesy of Nanomix)
Image: Nanōmix eLab system utilizes patented multi-plex test cartridge technology (Photo courtesy of Nanomix)

Sepsis, one of the leading causes of death, occurs when the immune system’s response to an infection spirals out of control. This can cause organ failure and other internal damage, and even death. For patients in sepsis, time to diagnosis is critical. Getting appropriate treatment right away leads to survival rates of roughly 80%. But for each hour that treatment is delayed, mortality rates increase by approximately 8%. Conventional sepsis tests can take hours or even days to generate results - far too long for optimal patient care. They are also expensive and must be run by skilled technicians in a hospital laboratory. Patients in sepsis would fare better with rapid, point-of-care testing. Now, a 11-minute critical infection test for use with a mobile, hand-held analyzer gives healthcare professionals more comprehensive information to make a sepsis diagnosis.

Nanōmix, Inc.’s (San Leandro, CA, USA) eLab system is a rapid, easy-to-use, quantitative detection platform that performs a range of in vitro diagnostic assays. The platform consists of a hand-held analyzer and a disposable cartridge. The Nanōmix eLab system utilizes patented multi-plex test cartridge technology designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings. The analyzer utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing.

Nanōmix’s first assays address the critical needs for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. Nanōmix’s 11-minute critical infection test for use with its handheld eLab analyzer covers three key biomarkers - lactate, procalcitonin (PCT), and C-reactive protein (CRP). First responders and other providers can use the Nanomix test for quick, on-the-spot assessment and triage of patients no matter where they are. Information that previously took hours to get through confirmatory testing is now available to clinicians dealing with patients suffering complex and non-specific symptoms. In 2019 Nanomix received CE Mark for this test, which is undergoing FDA 510(k) review and is currently the only test for the procalcitonin marker that can be performed outside of a laboratory. Additionally, Nanomix has received the EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for its eLab analyzer.

Related Links:
Nanomix Corporation 

Automated ELISA-IFA-BLOT Processor AP 22
New
Platinum Supplier
Hormonal Test
Endocrine Array
New
Silver Supplier
Modular Sequencing Workstation
MGIFLP-L200
New
Reusable Readers
Lumos Reusable Readers

Print article

Channels

Molecular Diagnostics

view channel
Image: A new machine rapidly and robustly separates cancer cells from blood samples (Photo courtesy of DGIST)

Centrifugal System for Separating Circulating Tumor Cells from Blood Samples to Improve Cancer Diagnosis

Circulating tumor cells are cells that break off from cancers and are released into the blood stream. They can go on to form the seeds for new tumor formation in other parts of the body, known as metastases.... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.